Lilly shares slip as FDA seeks more Alzheimer's drug data

Lilly said the U.S. Food and Drug Administration wants information from at least 100 patients who received a minimum of 12 months of continued treatment on donanemab. The drugmaker gave the update after markets closed Thursday.

Lilly said it had more than 100 patients in the study used for its accelerated approval application. But many were able to stop taking the drug as early as 6 months into treatment due to the reduction in plaque. Lilly is still seeking full approval for its drug. The company expects to report early results from a late-stage study in the second quarter.

And if this does not tell you that those working for Big Pharma are only in it for the money, nothing will.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Last walk-in clinic in Mallorytown, Ont. to close Friday - Kingston | Globalnews.caAround 60 clients per week from as far away as Seeley's Bay come to the Good Doctors Medical Clinics location in Mallorytown, but after Friday, it will be no more. So much for reliable government run health care. Sad!
Source: GlobalNational - 🏆 81. / 51 Read more »